Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Deloitte
Healthtrust
Accenture
Merck
Medtronic

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,166,243

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,166,243
Title:Optimizing mifepristone levels for cushing'S patients
Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
Inventor(s): Belanoff; Joseph (Woodside, CA), Gross; Coleman (Menlo Park, CA)
Assignee: Corcept Therapeutics, Inc. (Menlo Park, CA)
Application Number:16/146,032
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,166,243
Patent Claims: 1. A method of treating hypercortisolism in a patient, the method comprising: administering an initial daily dose of mifepristone to said patient, said initial daily dose comprising an initial dose amount of mifepristone; adjusting the dose amount of mifepristone to provide an adjusted daily dose of mifepristone if the plasma mifepristone level of the patient is less than 2000 ng/mL after administration of said initial daily dose of mifepristone, wherein said adjusting is performed in order to achieve a mifepristone plasma level of at least 2000 ng/mL; and administering to the patient said adjusted daily dose of mifepristone; with the proviso that the patient is not already suffering from a condition indicated for treatment with mifepristone, thereby treating hypercortisolism in the patient by achieving a mifepristone plasma level of at least 2000 ng/mL.

2. The method of claim 1, wherein said daily doses of mifepristone are administered orally.

3. The method of claim 1, wherein said initial daily dose of mifepristone contains at least 300 mg of mifepristone.

4. The method of claim 1, wherein said adjusted daily dose of mifepristone contains at least 600 mg of mifepristone.

5. The method of claim 1, wherein said adjusted daily dose of mifepristone contains at least 900 mg of mifepristone.

6. The method of claim 1, wherein said adjusted daily dose of mifepristone contains at least 1200 mg of mifepristone.

7. The method of claim 1, wherein the patient is treated with 7 or more daily doses of mifepristone over a period of 7 or more days.

8. The method of claim 1, wherein the patient is treated with 28 or more daily doses of mifepristone over a period of 28 or more days.

9. The method of claim 1, wherein adjusting the dose amount of mifepristone comprises increasing the amount of mifepristone of said adjusted daily dose in order to achieve mifepristone plasma levels of at least 2022 ng/mL.

10. The method of claim 1, wherein adjusting the dose amount of mifepristone comprises increasing the amount of mifepristone of said adjusted daily dose in order to achieve mifepristone plasma levels of at least 2100 ng/mL.

11. The method of claim 1, wherein adjusting the dose amount of mifepristone comprises increasing the amount of mifepristone of said adjusted daily dose in order to achieve mifepristone plasma levels of at least 2200 ng/mL.

12. The method of claim 1, wherein adjusting the dose amount of mifepristone comprises increasing the amount of mifepristone of said adjusted daily dose in order to achieve mifepristone plasma levels of at least 2300 ng/mL.

13. The method of claim 1, wherein the mifepristone plasma level comprises the trough plasma level of mifepristone.

14. The method of claim 9, wherein the achieved mifepristone plasma level comprises the trough plasma level of mifepristone.

15. The method of claim 10, wherein the mifepristone plasma level comprises the trough plasma level of mifepristone.

16. The method of claim 11, wherein the mifepristone plasma level achieved in said adjusting step comprises the trough plasma level of mifepristone.

17. The method of claim 12, wherein the mifepristone plasma level achieved in said adjusting step comprises the trough plasma level of mifepristone.

18. The method of claim 13, wherein the mifepristone plasma level achieved in said adjusting step comprises the trough plasma level of mifepristone.

19. The method of claim 1, wherein said patient suffers from ACTH dependent Cushing's syndrome.

20. The method of claim 7, wherein said patient suffers from ACTH dependent Cushing's syndrome.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
UBS
Queensland Health
QuintilesIMS
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.